A watershed in fighting cancer – but a miracle cure is a long way off | Charles Swanton

The latest advance in immunotherapy offers great hope, but there is much to learn before it can be translated into treatmentThese are exciting times to be a cancer researcher. The news this week that awoman ’s advanced breast cancer has apparently been eradicated by a therapy derived from her own immune system is a development many of us have waited a long time to hear. It ’spersonalised medicine, taken to the absolute limit, and a huge testimony to decades of hard work by a team of US researchers. And it ’s the sort of advance that genuinely deserves to be called a breakthrough.But those of us who treat people with advanced cancer have to balance the optimism of scientific progress with sober reality – this isn’t yet a cancer “treatment”, in the sense that is meaningful to our patients. The techniques used byDr Steve Rosenberg’s team at the US National Cancer Institute, and which many of us in the UK (including my own team) are also working on, are fearsomely complex, and currently far outside the routine clinical reality of an NHS cancer centre. That’s not because of funding, staff levels, or any of the other critic isms often levelled at our overstretched healthcare system – it’s because of the speed with which these insights have arrived. Naturally there will be a period of catch-up while they are tested more widely, and the infrastructure todeliver them routinely is put in place.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cancer research Breast cancer Medical research NHS Science Health Society UK news World news Source Type: news

Related Links:

University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The Department of Defense awarded more than $11 million for this Jacksonville study.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Triple-negative breast cancer (TNBC) is particularly aggressive, with enhanced incidence of tumor relapse, resistance to chemotherapy, and metastases. As the mechanistic basis for this aggressive phenotype is unclear, treatment options are limited. Here, we showed an increased population of myeloid-derived immunosuppressor cells (MDSCs) in TNBC patients compared with non-TNBC patients. We found that high levels of the transcription factor ΔNp63 correlate with an increased number of MDSCs in basal TNBC patients, and that ΔNp63 promotes tumor growth, progression, and metastasis in human and mouse TNBC cells. Furt...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer. J Clin Invest. 2018 Oct 08;: Authors: Kumar S, Wilkes DW, Samuel N, Blanco MA, Nayak A, Alicea-Torres K, Gluck C, Sinha S, Gabrilovich D, Chakrabarti R Abstract Triple-negative breast cancer (TNBC) is particularly aggressive, with enhanced incidence of tumor relapse, resistance to chemotherapy, and metastases. As the mechanistic basis for this aggressive phenotype is unclear, treatment options are limited. Here, we showed an increased population of myeloid-derived immunosuppressor c...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Invest Source Type: research
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had meta...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized breast cancer news Frontiers of Medicine Source Type: news
This study aimed to identify distinct molecular subtypes of BC and the clinical and/or biological characteristics of each subtype. We used seven gene expression data sets for bladder cancer, which included data from 118 primary bladder cancer samples and 27 recurrent bladder tumor tissues from the Yonsei University Severance Hospital. Hierarchical clustering revealed four molecular subtypes of BC with different clinical outcomes: class 1 with low-grade NMIBC and the best prognosis; class 2 characterized by active FGFR3 and inhibited immune response pathways; class 3 with high-grade NMIBC and the worst progression-free surv...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
AbstractBreast cancer remains one of the leading causes of cancer-associated death worldwide. Conventional treatment is associated with substantial toxicity and suboptimal efficacy. We, therefore, developed and evaluated the in vitro efficacy of an autologous dendritic cell (DC) vaccine to treat breast cancer. We recruited 12 female patients with stage 1, 2, or 3 breast cancer and matured their DCs with autologous tumour-specific lysate, a toll-like receptor (TLR)-3 and 7/8 agonist, and an interferon-containing cocktail. The efficacy of the vaccine was evaluated by its ability to elicit a cytotoxic T-lymphocyte response to...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. “I think this is going to change the paradigm of treating mesotheliom...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsIbuprofen administration during the tumor promotional microenvironment of the involuting mammary gland reduces overall tumor growth and enhances anti-tumor immune characteristics while avoiding adverse autoimmune reactions. In sum, these studies implicate beneficial prophylactic use of ibuprofen during the pro-tumorigenic window of mammary gland involution.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
AbstractBreast cancer (BCa) is a heterogeneous disease with different histological, prognostic and clinical aspects. Therefore, the need for identification of novel biomarkers for diagnosis, prognosis and monitoring of disease, as well as treatment outcome prediction remains at the forefront of research. The search for circulating elements, obtainable by simple peripheral blood withdrawal, which may serve as possible biomarkers, constitutes still a challenge. In the present study, we have evaluated the expression of 6 circulating miRNAs, (miR-16, miR-21, miR-23 α, miR-146α, miR-155 and miR-181α), in opera...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Funding | Immunotherapy | Learning | Research | Science | Universities & Medical Training